[144] Ascendis Pharma A/S American SEC Filing

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) filed a Form 144 notifying the proposed sale of 9,375 American Depositary Shares on 08/15/2025 through Merrill Lynch on NASDAQ. The filing reports an aggregate market value of $1,826,403.05 and total shares outstanding of 60,454,589. The shares were acquired the same day by warrant exercise from Ascendis Pharma A/S, with cash payment. The filer reports no securities sold in the past three months. The notice includes the standard signature representation that the seller is not aware of any undisclosed material adverse information.

Insights

Financial Analyst

TL;DR Routine notification of a small block sale of ADSs acquired by warrant exercise; no recent selling activity reported.

The Form 144 documents a proposed sale of 9,375 ADSs with an aggregate value of $1.83 million, to be executed on 08/15/2025 via Merrill Lynch on NASDAQ. The securities were acquired the same day by warrant exercise and paid for in cash. The filer indicates no sales in the prior three months, suggesting this filing represents an isolated disposition rather than sustained selling. The disclosure is procedural and provides limited new information about company operations or financial condition.

Corporate Governance Expert

TL;DR Administrative compliance filing that fulfills Rule 144 notice requirements; includes standard attestation about undisclosed material information.

The submission meets Rule 144 notice requirements by identifying the class of securities, broker, number of ADSs, aggregate market value, share count outstanding, acquisition method and payment. The filing contains the customary attestation regarding the absence of undisclosed material adverse information and notes no sales in the prior three months. There are no governance changes, insider departures, or other corporate actions disclosed in this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	9375	1826403.05	60454589	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	08/15/2025	Warrant exercise	Ascendis Pharma A/S			9375	08/15/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)